Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis

Monoclonal antibodies (mAbs) to ErbB-2/HER2 or to its sibling, the epidermal growth factor receptor (EGFR), prolong survival of cancer patients, especially when combined with cytotoxic therapies. However, low effectiveness of therapeutic mAbs and the evolution of patient resistance call for improvements. Here we test in animals pairs of anti-ErbB-2 mAbs and report that pairs comprising an antibody reactive with the dimerization site of ErbB-2 and an antibody recognizing another distinct epitope better inhibit ErbB-2-overexpressing tumors than other pairs or the respective individual mAbs. Because the superiority of antibody combinations extends to tumor cell cultures, we assume that nonimmunological mechanisms contribute to mAb synergy. One potential mechanism, namely the ability of mAb combinations to instigate ErbB-2 endocytosis, is demonstrated. Translation of these lessons to clinical applications may enhance patient response and delay acquisition of resistance.

[1]  H. Cremer,et al.  NCAM is ubiquitylated, endocytosed and recycled in neurons , 2007, Journal of Cell Science.

[2]  K. Gelmon,et al.  Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T , 2007 .

[3]  B. Robert,et al.  In vivo Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas , 2007, Clinical Cancer Research.

[4]  Yosef Yarden,et al.  Cancer therapeutic antibodies come of age: Targeting minimal residual disease , 2007, Molecular oncology.

[5]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[6]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[7]  Y. Yarden,et al.  Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  E. Vitetta,et al.  A Comparison of the in Vitro and in Vivo Activities of IgG and F(ab′)2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies , 2004, Clinical Cancer Research.

[9]  M. Hung,et al.  The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells , 2004, Cancer Research.

[10]  Y. Yarden,et al.  Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases , 2004, Oncogene.

[11]  Michael Kofler,et al.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.

[12]  S. Emr,et al.  Receptor downregulation and multivesicular-body sorting , 2002, Nature Reviews Molecular Cell Biology.

[13]  Brian Higgins,et al.  Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.

[14]  J. Uhr,et al.  Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  J. Koch,et al.  Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design1 , 2001, The Journal of Immunology.

[16]  Y. Yarden,et al.  Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. , 2000, Cancer research.

[17]  M. Wilchek,et al.  Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies , 2000, Cancer Immunology, Immunotherapy.

[18]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[19]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Wiley,et al.  ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors* , 1999, The Journal of Biological Chemistry.

[21]  Yosef Yarden,et al.  A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.

[22]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[23]  G. Carpenter,et al.  All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.

[24]  J. Mendelsohn,et al.  Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. , 1994, The Journal of biological chemistry.

[25]  C. Arteaga,et al.  p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. , 1994, Cancer research.

[26]  Yinhua Yu,et al.  Antibody‐induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c‐erbb‐2 (her‐2/neu) gene product p185 , 1993, International journal of cancer.

[27]  P. P. Di Fiore,et al.  Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. , 1992, Cancer research.

[28]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Ullrich,et al.  Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Y. Yarden,et al.  Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Steinberg,et al.  Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. , 1989, Cancer research.

[32]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[33]  M. Greene,et al.  Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. , 1988, Oncogene.

[34]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[35]  R. Weinberg,et al.  Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[36]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.